|Year : 2012 | Volume
| Issue : 2 | Page : 94-96
Declining total leucoyte count, an indication of transient abnormal myelopoisis
Yogesh K Yadav1, Varuna Mallya2, Oneal Gupta3
1 Department of Pathology, Integral Institute of Medical Sciences and Research, Lucknow, Uttar Pradesh, India
2 Department of Pathology, Army College of Medical Sciences and Base Hospital, New Delhi, India
3 Department of Pathology, Safdarjung Hospital and V. M. M. College, New Delhi, India
|Date of Web Publication||10-Aug-2012|
Yogesh K Yadav
Assistant Professor, 145, A-Block, South City, Rae Barely Road, Lucknow, Uttar Pradesh - 226025
Source of Support: None, Conflict of Interest: None
Neonates with Down syndrome have an increased predisposition to transient abnormal myelopoisis, a haematological abnormality which is characterized by uncontrolled proliferation of myeloblasts. The unique ability of this disorder to spontaneously enter in to a state of remission led to the creation of a new class in 2008 World Health Organization (W.H.O.) classification of haemopoitic and lymphoid tumours. It has now been classified as transient abnormal myelopoisis (TAM). The cause of remission is still not clear although it is possibly linked to the abnormal expression of GATA-1 transcription factor and to a switch from hepatic haematopoesis to medullary haematopoesis. Simple laboratory monitoring by serial complete blood count and peripheral smear can give indication of this rare disorder. As very few cases of this disorder exist we share our experience and report a case of transient myeloproliferative disorder in a male newborn having Down syndrome.
Keywords: Down syndrome, megakaryoblastic leukemia, transient abnormal myelopoisis
|How to cite this article:|
Yadav YK, Mallya V, Gupta O. Declining total leucoyte count, an indication of transient abnormal myelopoisis. Clin Cancer Investig J 2012;1:94-6
|How to cite this URL:|
Yadav YK, Mallya V, Gupta O. Declining total leucoyte count, an indication of transient abnormal myelopoisis. Clin Cancer Investig J [serial online] 2012 [cited 2020 Apr 5];1:94-6. Available from: http://www.ccij-online.org/text.asp?2012/1/2/94/99580
| Introduction|| |
Transient abnormal myelopoisis (TAM) is a haematological abnormality that is characterized by uncontrolled proliferation of myeloblasts in the peripheral blood and bone marrow. In most instances, this disorder has the ability to spontaneously "turn off" the overproduction and enter a state of remission. , The disorder is seen especially in infants with Down syndrome in neonatal period and requires supportive treatment in majority of the cases. , As very few cases of this disorder exist we share our experience and report a case of transient myeloproliferative disorder in a newborn male with Down syndrome.
| Case Report|| |
A new born male child, born at 37 weeks of gestation, weighed three kilograms at birth and was large for date. Examination revealed features of Down syndrome, pedal edema, hepatosplenomegaly. Antenatal scan revealed pericardial effusion. Ultrasound of the abdomen confirmed hepatosplenomegaly. Haematological examination on day one showed hemoglobin of 15.2 gram percent, Total leucocyte count (TLC) of 78,500 cells per microliter, platelets were 1,41,000 per microliter. Peripheral smear showed cells that measured 12-15 micrometer with round to irregular nuclei and a basophilic cytoplasm along with cytoplasmic blebs and were consistent with blasts. The cytoplasm of blasts cells showed azurophilic granules. These blasts constituted 55% of TLC [Figure 1]. Samples was taken on every day and sent for complete blood count. Samples showed declining TLC till it reached normal level at day ten [Figure 2]. On day ten TLC declined to 12500 which was normal for age and platelets were 1,75,000 per microliter.
|Figure 1: Peripheral smear showing blasts with open chromatin irregular nuclear membrane and scanty basophilic granular cytolplasm revealing blebbing - arrow mark. (Giemsa stain ×1000)|
Click here to view
|Figure 2: Graph showing declining Total leucocyte count per microliter from day one to day ten after birth|
Click here to view
The bone marrow examination was done on the day seven, which was diluted with blood and comprised predominately of blasts cells [Figure 3]. Blasts have similar morphology as in the peripheral blood. Cytoplasmic blebs were appreciated in majority of blasts, their cytoplasm contained coarse granules. Mature cells of neutrophilic lineage were reduced.
|Figure 3: Bone marrow smear was diluted with blood and comprised predominately of blasts cells, note the blebbing in blasts - arrow mark. (Giemsa stain ×1000)|
Click here to view
Flow cytometry of bone marrow aspirate revealed that the blasts were positive for CD34, CD13, CD33, CD41, and CD61.
Karyotyping done on day seven revealed trisomy at 21 chromosomes [Figure 4].
The reducing TLC along with peripheral smear, bone marrow, karyotyping, flow cytometric findings along with clinical features and physical examination were consistent with a diagnosis of transient myeloproliferative disorder in the infant with Down syndrome.
| Discussion|| |
Individuals with Down syndrome have an increased predisposition to acute leukemias, predominantly of myeloid type. ,,,, The major morphological subtype appears to be acute megakaryoblastic leukemia. Sometimes leukemia undergoes spontaneous remission and is referred as transient abnormal myelopoisis (TAM). TAM is characterized by excessive proliferation of myeloblast in the peripheral blood and bone marrow. ,, This unique ability of this disorder to spontaneously enter in to a state of remission led to the creation of new class in 2008 World Health Organization (W.H.O.) classification of haemopoitic and lymphoid tumours.  It's now been classified as TAM with ICD-O code 9898/1, under the category, "myeloid proliferations related to down syndrome".  In the previous W.H.O. classification (2001) it was classified as a variant of acute megakaryoblastic leukemia and was called as transient myeloproliferative disorder.  The lack of GATA-1 transcription factor results in accumulation of abnormally differentiated megakaryocytes without leukemic transformation.  There is a strong association of down syndrome's acute megakaryocytic leukemia to the mutations in X-linked haemopoitic transcription factor GATA-1.  Approximately 10% of infants with Down syndrome have TAM. It is estimated that 25% of these infants, who present with TAM, are likely to develop megakaryoblastic leukemia between the age group of 1 to 3 years. , The spontaneous remission of TAM has been linked to switch from hepatic haematopoisis to medullaryhaematopoesis.  The initiation of chemotherapy is an important decision for the management, though it is not always required. Supportive care is recommended for TMD during the first few months of life unless the clinical condition requires intervention.  Initial treatment options for TMD include leucopheresis or exchange transfusion. Chemotherapeutic drugs halt tumour cell division and are indicated in hyperviscosity syndrome, organomegaly causing respiratory distress, congestive heart failure, pericardial effusion, hydrops fetalis, liver dysfunction, and disseminated intravascular coagulation.  Low doses of cytosine arabinoside are recommended as the chemotherapeutic agent of choice.  The dose, duration, and frequency of medicine administration are often dependent on the size and type of cancer. The therapeutic effect is not apparent until 3 to 4 days after the initiation of chemotherapy. In this case the disorder spontaneously entered in to the state of remission with out any specific intervention.
A differential diagnosis of septicemia with leukamoid reaction was considered in our case in view of the peripheral smear findings, the diagnosis of transient abnormal myelopoisis (TAM) was confirmed based on bone marrow and flow cytometric findings.
Simple laboratory monitoring by serial complete blood count and peripheral smear can give indication of this rare disorder. We suggest that extensive research is needed to study the mechanism behind its evolution and management of this disorder.
| References|| |
|1.||Rhoderick JN, Bradshaw WT, King C. Transient myeloproliferative disorder in a newborn with Down syndrome. Adv Neonatal Care 2008; 8:208-18. |
|2.||Brink DS. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome. Adv Anat Pathol 2006; 13:256-62. |
|3.||Shenoy RD, Bhat KG, Kamath N, Kumble Y. Transient myeloproliferative disorder and eosinophilic pericardial effusion in a down syndrome neonate. Pediatr Hematol Oncol 2008; 25:123-9. |
|4.||D'Angelo G, Merlo P. Transient myeloproliferative syndrome/transient acute myeloid leukemia in a newborn with Down syndrome: A case report and literature review. Lab Hematol 2003; 9:38-41. |
|5.||Zarina AL, Hamidah A, Yong SC, Rohana J, Hamidah NH, Azma RZ, et al. Transient abnormal myelopoeisis in newborns with Down syndrome. Malays J Pathol 2007; 29:107-11. |
|6.||Swerdlow SH, Campo E, Jaffe ES, Harris NL, Pileri SA, Stein H, et al. World Health Organization classification of tumours: Pathology and genetics of tumours ofhaematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press; 2008. p. 142- 3. |
|7.||Vardiman JW, Jaffe ES, Harris NL, Stein H.World Health Organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. 3rd ed. Lyon, France: IARC Press; 2001. p. 101-2. |
|8.||Hitzer J, Cheung J, Li Y, Scherer S, Zipursky A. GATA-1 mutations in transient leukemia acute megakaryoblastic leukemia of Down syndrome. Blood 2003; 101:4301-4. |
|9.||Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O'Marcaigh A, et al. Natural history of GATA-1 mutations in Down syndrome. Blood 2004; 103:2480-9. |
|10.||Al-Kasim F, Doyle J, Massey G, Weinstein H, Zipursky A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric oncology group study. J Pediatr Hematol Oncol 2002; 24:9-13. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]